Corticotropin-releasing factor receptor antagonists
- 21 June 2006
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 16 (7) , 913-924
Abstract
Corticotropin-releasing factor (CRF) coordinates the neural, endocrine and immune responses of the body to stress. Therefore, CRF receptors are important targets for the design of drugs for depression, anxiety and stress-related disorders. Several laboratories have published extensive preclinical and limited clinical research into the role of CRF in human disease. This review covers developments in the patent literature during 2002 - 2006 and outlines the prospects for CRF-based therapy for mental illness.Keywords
This publication has 25 references indexed in Scilit:
- The role of CRF receptors in anxiety and depression: Implications of the novel CRF1 agonist cortagineNeuroscience & Biobehavioral Reviews, 2005
- CRF and CRF Receptors: Role in Stress Responsivity and Other BehaviorsAnnual Review of Pharmacology and Toxicology, 2004
- Small molecule corticotropin-releasing factor antagonistsExpert Opinion on Therapeutic Patents, 2002
- Treatment of mood disordersNature Neuroscience, 2002
- The CRF peptide family and their receptors: yet more partners discoveredTrends in Pharmacological Sciences, 2002
- A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: Implications for the design of agonists and antagonistsProceedings of the National Academy of Sciences, 2001
- Research and treatment approaches to depressionNature Reviews Neuroscience, 2001
- Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treatedJournal of Psychiatric Research, 2000
- Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic AgentsJournal of Medicinal Chemistry, 2000
- Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): Development of CRFR2β-selective antisauvagine-30Proceedings of the National Academy of Sciences, 1998